At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 19 enrolled
Drug / intervention
APX3330drug
Likely dose
APX3330 120 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Study of APX3330 in Patients With Advanced Solid Tumors
In Brief
A Phase 1 clinical trial evaluating APX3330 for Cancer. Completed, enrolled 19 participants across 3 sites.
Detailed Summary
This is a Phase 1, multi-center, open-label, dose-escalation oncology study of APX3330 in patients with advanced solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedDec 2017
Enrollment StartJan 2018
Primary CompletionAug 2018
Study CompletionJan 2019
TodayJul 2026
First PostedDec 15, 2017
Enrollment StartJan 30, 2018
Primary CompletionAug 18, 2018
Study CompletionJan 9, 2019
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 8.5 years ago
Interventions
APX3330drug
APX3330 will be supplied as 60 and 120 mg orally administered tablets. Patients will receive a fixed dose of APX3330 twice daily (i.e., bid) each day of a 21-day cycle. The starting dose of APX3330 will be a daily dose of 240 mg (i.e., 120 mg/dose bid). Doses will be increased until identification of a maximum tolerated dose or bio-effective dose, whichever is lower.